NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · ALXO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ALX Oncology Holdings Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ALX Oncology Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 6, 2025 |
| -$0.55+23.61% vs estimate |
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$0.58+25.64% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$122.60+$0.09 (+0.07%)
Kymera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
$26.35-$0.06 (-0.23%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.49% below the high.
$10.87+$0.02 (+0.18%)
Monte Rosa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.82% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$3.82-$0.06 (-1.55%)
Bicycle Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$1.66-$0.06 (-3.49%)
Nkarta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.38% below the high.
$0.40-$0.01 (-1.34%)
Tenaya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.46% below the high.
